Pfizer and its partner BioNTech said Thursday they have started evaluating a combination COVID 19-flu vaccine using the companies' Omicron booster.
Why it matters: A combined vaccine could simplify immunizations and simultaneously fight two respiratory diseases that require repeated vaccinations.
- Moderna and Novavax are also developing combination COVID and flu shots.
Details: Pfizer and BioNTech aim to enroll 180 U.S. volunteers between the ages of 18 and 64 for an early-stage trial to assess the safety, efficacy and optimal dosage. The first participant received a dose of the combination shot this week.
- The candidate vaccine combines an mRNA influenza vaccine with the companies' COVID-19 shot based on the BA.4 BA.5 variants.
Between the lines: While COVID case counts remain low in the U.S., public health efforts are increasingly focused on new ways to address multiple threats, like a "tripledemic" of more transmissible variants, a major uptick in RSV cases and worse-than-usual flu season.
Recommended Comments
There are no comments to display.
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.